Discontinuing Blood Thinner Therapy After Successful Atrial Fibrillation Treatment May Reduce Risks

Recent research suggests that stopping oral anticoagulation (OAC) medication after a successful atrial fibrillation (AF) ablation procedure could lower the risk of adverse events such as stroke, systemic embolism, and major bleeding. A large trial presented at ESC Congress 2025 and published in the Journal of the American Medical Association examined patients who had undergone their first catheter-based AF ablation at least 12 months prior. These patients had no recurrence of arrhythmia and possessed at least one stroke risk factor based on the CHA2DS2-VASc score.

The trial involved 840 participants randomized equally into two groups: one continuing standard-dose OAC therapy, primarily with apixaban, rivaroxaban, or edoxaban, and the other stopping anticoagulation altogether. Over 24 months, the group that discontinued OAC experienced fewer net adverse clinical events—only 0.3% compared to 2.2% in the continuing therapy group. Interestingly, there was no significant difference in the rates of ischemic stroke or systemic embolism between the groups, with incidences of less than 1% in both.

However, major bleeding was more common in the OAC group, affecting 1.4% of patients, while the no-OAC group had no major bleeding events. Although the study's primary goal was to evaluate overall adverse events, the findings imply that lifelong anticoagulation may not be necessary for all patients after successful AF ablation, especially those without recurrent arrhythmia.

Professor Boyoung Joung from Yonsei University, Seoul, emphasized that this trial is the first to provide randomized evidence that stopping OAC can be safer in select patients, challenging the current guideline recommendations for indefinite anticoagulation based solely on stroke risk factors. Nonetheless, as the trial was not specifically powered to detect differences in ischemic events, further research is needed.

Overall, these findings may influence future guidelines and patient management strategies, potentially reducing the long-term use of blood-thinning medications in patients who have achieved rhythm control after AF ablation. Patients should consult their healthcare providers to individualize treatment decisions based on their specific risk profiles.

Source: MedicalXpress